Heron Therapeutics (NASDAQ:HRTX) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Thursday.

HRTX has been the topic of a number of other reports. Noble Financial reiterated a “buy” rating and issued a $24.00 price target on shares of Heron Therapeutics in a report on Friday, October 6th. Cantor Fitzgerald reiterated a “buy” rating on shares of Heron Therapeutics in a report on Monday, September 25th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. Cowen reiterated a “buy” rating and issued a $40.00 price target on shares of Heron Therapeutics in a report on Monday, November 6th. Finally, Oppenheimer initiated coverage on shares of Heron Therapeutics in a report on Monday, October 30th. They issued a “buy” rating and a $27.00 price target on the stock. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $28.73.

Shares of Heron Therapeutics (NASDAQ:HRTX) traded up $0.65 during midday trading on Thursday, reaching $17.60. 1,295,910 shares of the company’s stock were exchanged, compared to its average volume of 819,861. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12. Heron Therapeutics has a one year low of $12.21 and a one year high of $18.40.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.10. The company had revenue of $8.57 million for the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. equities analysts forecast that Heron Therapeutics will post -3.42 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC bought a new stake in shares of Heron Therapeutics in the 2nd quarter worth about $78,134,000. Virtu KCG Holdings LLC increased its holdings in shares of Heron Therapeutics by 62.5% in the 2nd quarter. Virtu KCG Holdings LLC now owns 25,053 shares of the biotechnology company’s stock worth $347,000 after buying an additional 9,637 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Heron Therapeutics by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock worth $2,837,000 after buying an additional 14,086 shares during the last quarter. C WorldWide Group Holding A S bought a new stake in shares of Heron Therapeutics in the 3rd quarter worth about $1,615,000. Finally, Teachers Advisors LLC grew its holdings in Heron Therapeutics by 20.5% during the 1st quarter. Teachers Advisors LLC now owns 69,720 shares of the biotechnology company’s stock valued at $1,046,000 after purchasing an additional 11,862 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “Heron Therapeutics (HRTX) Upgraded to “Hold” by ValuEngine” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/30/heron-therapeutics-hrtx-upgraded-to-hold-by-valuengine.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.